Janssen P A, Janssen H, Cauwenbergh G, De Doncker P, De Beule K, Lewi P, Tytgat H F, Lapière C M
Janssen Research Foundation, Beerse, Belgium.
J Am Acad Dermatol. 1989 Jul;21(1):85-90. doi: 10.1016/s0190-9622(89)70153-5.
The use of a 2% ointment formulation of ketanserin, an S2-serotoninergic blocking agent, was investigated in a randomized double-blind clinical trial for its effect on the healing of wounds of patients with decubitus, venous, and ischemic skin ulcers. The result demonstrates a significant difference in favor of the ketanserin-treated group (35 patients) versus the placebo-treated group (37 patients) on the basis of two factors: formation of granulation tissue and epithelialization. In addition, a significant difference of 150% in the initial velocity of wound closure was observed in favor of the patients treated with ketanserin. This effect was persistent during the entire study period.
